Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
May 12  •  11:53AM ET
1.35
Dollar change
-0.00
Percentage change
-0.07
%
May 11, 6:15 PMMetagenomi Therapeutics Inc reports fiscal Q1 2026 results with non-GAAP EPS $-0.61 (+10% YoY) and revenue $1.2M (-70% YoY), misses EPS and revenue estimates
Index
-
P/E
-
EPS (ttm)
-2.29
Insider Own
31.03%
Shs Outstand
37.65M
Perf Week
-4.33%
Market Cap
50.75M
Forward P/E
-
EPS next Y
-1.68
Insider Trans
-0.15%
Shs Float
25.95M
Perf Month
-3.64%
Enterprise Value
-50.22M
PEG
-
EPS next Q
-0.59
Inst Own
18.19%
Perf Quarter
-14.08%
Income
-85.89M
P/S
2.27
EPS this Y
6.92%
Inst Trans
4.77%
Perf Half Y
-37.55%
Sales
22.33M
P/B
0.37
EPS next Y
23.68%
ROA
-34.71%
Perf YTD
-16.73%
Book/sh
3.66
P/C
0.36
EPS next 5Y
2.65%
ROE
-49.02%
52W High
3.95 -65.85%
Perf Year
-12.97%
Cash/sh
3.73
P/FCF
-
EPS past 3/5Y
-26.57% -42.49%
ROIC
-50.27%
52W Low
1.25 7.92%
Perf 3Y
-
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
13.59% 219.15%
Gross Margin
76.56%
Volatility
4.19% 4.88%
Perf 5Y
-
Dividend TTM
-
EV/Sales
-2.25
EPS Y/Y TTM
9.77%
Oper. Margin
-415.48%
ATR (14)
0.07
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
6.43
Sales Y/Y TTM
-50.66%
Profit Margin
-384.61%
RSI (14)
40.78
Dividend Gr. 3/5Y
- -
Current Ratio
6.43
EPS Q/Q
9.28%
SMA20
-5.73%
Beta
0.65
Payout
-
Debt/Eq
0.28
Sales Q/Q
-69.76%
SMA50
-6.35%
Rel Volume
1.19
Prev Close
1.35
Employees
119
LT Debt/Eq
0.24
SMA200
-26.42%
Avg Volume
207.62K
Price
1.35
IPO
Feb 09, 2024
Option/Short
No / Yes
Trades
Volume
98,006
Change
-0.07%
Date Action Analyst Rating Change Price Target Change
May-07-24Initiated H.C. Wainwright Buy $10
May-02-24Downgrade JP Morgan Overweight → Neutral $16 → $6
Mar-05-24Initiated Wells Fargo Overweight $25
Mar-05-24Initiated TD Cowen Outperform
Mar-05-24Initiated JP Morgan Overweight $16
Mar-05-24Initiated Jefferies Buy $23
Mar-05-24Initiated Chardan Capital Markets Buy $21
Mar-05-24Initiated BMO Capital Markets Outperform $22
May-11-26 04:18PM
04:05PM
Apr-16-26 07:00AM
Apr-13-26 12:15PM
Mar-05-26 05:30PM
04:28PM Loading…
04:28PM
04:05PM
Feb-26-26 05:30PM
Feb-23-26 04:05PM
Jan-12-26 08:30AM
Dec-02-25 12:32PM
Dec-01-25 07:00AM
Nov-17-25 08:00AM
Nov-12-25 05:20AM
Nov-11-25 05:10PM
04:09PM Loading…
04:09PM
04:02PM
04:01PM
Nov-10-25 05:45PM
Nov-06-25 08:50AM
Nov-05-25 05:35PM
Oct-22-25 10:02AM
Oct-20-25 12:00PM
Aug-12-25 05:40PM
05:25PM
04:37PM
04:05PM
Aug-11-25 04:05PM
Aug-07-25 08:35AM
Jul-29-25 10:23AM
10:06AM Loading…
Jul-18-25 10:06AM
09:41AM
Jul-14-25 11:12AM
May-14-25 06:00AM
May-13-25 05:40PM
04:42PM
04:30PM
May-08-25 09:30AM
May-06-25 07:15AM
May-02-25 07:00AM
Apr-01-25 11:50AM
Mar-17-25 04:05PM
Mar-13-25 06:19AM
Feb-11-25 08:55AM
Jan-28-25 08:00AM
Jan-22-25 11:54AM
Jan-16-25 08:55AM
Jan-15-25 08:55AM
Jan-08-25 04:05PM
Dec-11-24 06:30PM
Dec-09-24 09:16PM
Dec-08-24 06:05AM
Nov-18-24 12:00PM
Nov-13-24 04:37PM
04:05PM
Nov-05-24 04:05PM
Oct-29-24 05:45AM
Oct-24-24 08:04AM
Oct-23-24 05:45AM
Oct-14-24 08:58PM
Oct-01-24 03:14PM
Sep-19-24 07:15PM
Sep-03-24 04:05PM
Aug-29-24 07:32PM
Aug-28-24 06:10PM
Aug-26-24 09:00PM
Aug-14-24 08:11AM
08:05AM
Aug-12-24 06:29PM
Aug-05-24 09:00PM
Jun-03-24 04:30PM
04:17PM
May-29-24 04:00PM
May-14-24 10:54PM
04:05PM
May-04-24 10:49AM
May-02-24 06:04AM
May-01-24 04:00PM
01:53PM
Apr-08-24 08:00AM
Mar-27-24 09:16AM
Feb-29-24 04:30PM
Feb-13-24 04:35PM
Feb-08-24 10:16PM
Metagenomi Therapeutics, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wapnick PamelaChief Financial OfficerMar 05 '26Sale1.601,5812,530187,375Mar 09 05:16 PM
Wein MatthewSee RemarksMar 05 '26Sale1.60482771114,549Mar 09 05:16 PM
Irish JianChief Executive OfficerMar 05 '26Sale1.601,6072,571333,770Mar 09 05:15 PM
Thomas Brian C.DirectorDec 05 '25Sale1.773,8306,7862,510,960Dec 08 01:56 PM
Wein MatthewSee RemarksDec 05 '25Sale1.77199353115,031Dec 08 01:51 PM
Wapnick PamelaChief Financial OfficerDec 05 '25Sale1.771,5762,793188,956Dec 08 01:49 PM
Irish JianChief Executive OfficerDec 05 '25Sale1.771,6022,839563,839Dec 08 01:38 PM
Thomas Brian C.DirectorSep 05 '25Sale1.812,7014,8892,514,790Dec 01 07:34 PM
Wapnick PamelaChief Financial OfficerSep 05 '25Sale1.811,5762,85370,532Dec 01 07:32 PM
Irish JianChief Executive OfficerSep 05 '25Sale1.811,6022,900316,941Dec 01 07:28 PM
Wein MatthewSee RemarksSep 05 '25Sale1.8119936019,230Dec 01 06:37 PM
Noonberg Sarah B.FORMER OFFICERSep 11 '25Proposed Sale1.9035,83268,081Sep 11 04:25 PM
Sebastian BernalesAffiliateJul 09 '25Proposed Sale1.91769,8451,470,404Jul 09 06:34 PM
Wein MatthewSee RemarksJun 06 '25Sale1.7519934816,693Jun 09 07:04 PM
Noonberg Sarah B.Chief Medical OfficerJun 06 '25Sale1.755,2399,168109,135Jun 09 06:57 PM
Wapnick PamelaChief Financial OfficerJun 06 '25Sale1.751,5762,75872,108Jun 09 06:54 PM
Thomas Brian C.Chief Executive OfficerJun 06 '25Sale1.7510,78518,8742,517,491Jun 09 06:50 PM
Irish JianSee RemarksJun 06 '25Sale1.756,39011,182315,543Jun 09 06:20 PM